947 resultados para Mink, Mark
Resumo:
We develop a model of comparative advantage with monopolistic competition, that incorporates heterogeneous firms and endogenous mark-ups. We analyse how these features vary across countries with different factor endowments, and across markets of different size. In this model we can obtain trade gains via two channels. First, when we open the economy, most productive firms start to export their product, then, they demand more producing factors and wages rises, thus, those firms that are less productive will be forced to stop to produce. Second channel is via endogenous mark-ups, when we open the economy, the competition gets ``tougher'', then, mark-ups falls, thus, those firms that are less productive will stop to produce. We also show that comparative advantage works as a ``third channel'' of trade gains, because, all trade gains results are magnified in comparative advantage industry of both countries. We also make a numerical exercise to see how endogenous variables of the model vary when trade costs fall.
Resumo:
Heterotermes tenuis is an important economic pest in São Paulo state. Foraging populations of three field colonies of H. tenuis located on a University campus (UNESP, Rio Claro, SP, Brazil) were characterized. Foraging populations of H. tenuis colonies were calculated using four cycles of a mark-release-recapture program with a weighted mean method. The foraging population sizes of three colonies: A, B and C were 389,313±14,907; 265,589 ±12,635; and 641,600∓12,127; respectively. Foraging biomasses were 0.77 kg in the colony A, 0.51 kg in the colony B and 1.17 kg in colony C. Mean worker biomass was approximately 1.9 mg. Foraging territories occupied an area ranging from 70 m2 to 131 m2 per colony. The maximum linear foraging distance traveled by H. tenuis was 28m.
Resumo:
Includes bibliography
Resumo:
Pós-graduação em Letras - FCLAS
Resumo:
President Williamson, honored guests and friends, it is such a pleasure to be here with you tonight, and such a privilege to deliver this tribute to our 2004 Nebraska Hall of Agricultural Achievement honorees, Rod Gangwish and Mark Gustafson.
Resumo:
Few Nebraskans are as devoted to the University of Nebraska as Mark Gustafson. Driven by his belief that a strong university is key to a strong Nebraska economy, Mark is an advocate for the university in the local, state, and national arenas. He is a Nebraska delegate to the Council for Agricultural, Research, Extension, and Teaching, a national advocacy organization for higher education. Since 1991, he's been a member of Agriculture Builders of Nebraska, Inc., which supports UNL's Institute of Agriculture and Natural Resources, as well as the entire University, and has served three terms as president. He has served on the advisory councils for the UNL chancellor and the NU president and served on UNL's Future Nebraska Taskforce. He holds baccalaureate and master's degrees from UNL and a Ph.D. from the University of California-Berkeley. When he's not volunteering his time, Mark operates the family farm near Mead. He and his wife, Dianne, are the parents of two children - Christopher, a UNL alumnus, and Anneke, a UNL junior.
Resumo:
According to the latest statistics projections formulated by Eurostat, the proportion of elderly EU-27’s population aged over 65 years old is predicted to increase from 17.5 % in 2011 to 29.5 % by 2060. This "population explosion" makes extremely important to identify the different genetic and molecular mechanisms which underpin the morbidity and mortality along with new strategies able to counteract or slow down its progress. In this scenario fits the European Project MARK-AGE whose aim was to identify a robust set of biomarkers of human ageing able to discriminate between chronological and biological ageing and to derive a model for healthy ageing through the analysis of three populations from different European countries, supposed to be characterized by different ageing rate: 1. Subjects representing the “Normal” or “Physiological” aging. 2. Subjects representing the “successful” or “decelerate” aging 3. Subjects representing the “accelerated” aging. The aim of this work was to recruit and characterize volunteers, to perform an accurate analysis of the health status of elderly recruited subjects (60-79 years) verifying any possible dissimilarity in their aging trajectories, to identify a set of robust ageing biomarkers and investigate possible correlations between ageing biomarkers and health status of recruited volunteers. The model proposed by MARK-AGE Project regarding different ageing trajectories has been confirmed and several ageing biomarkers have been identified.
Resumo:
It is of interest in some applications to determine whether there is a relationship between a hazard rate function (or a cumulative incidence function) and a mark variable which is only observed at uncensored failure times. We develop nonparametric tests for this problem when the mark variable is continuous. Tests are developed for the null hypothesis that the mark-specific hazard rate is independent of the mark versus ordered and two-sided alternatives expressed in terms of mark-specific hazard functions and mark-specific cumulative incidence functions. The test statistics are based on functionals of a bivariate test process equal to a weighted average of differences between a Nelson--Aalen-type estimator of the mark-specific cumulative hazard function and a nonparametric estimator of this function under the null hypothesis. The weight function in the test process can be chosen so that the test statistics are asymptotically distribution-free.Asymptotically correct critical values are obtained through a simple simulation procedure. The testing procedures are shown to perform well in numerical studies, and are illustrated with an AIDS clinical trial example. Specifically, the tests are used to assess if the instantaneous or absolute risk of treatment failure depends on the amount of accumulation of drug resistance mutations in a subject's HIV virus. This assessment helps guide development of anti-HIV therapies that surmount the problem of drug resistance.